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CDKN2A mutations in Scottish families with cutaneous melanoma: results from
32 newly identified families
Thirty two newly identified families in Scotland with melanoma in two or more
first-degree relatives were investigate for mutations in the CDKN2A gene. Seven of
the 32 melanoma families (22%) have CDKN2A mutations. One mutation, H83N,
not previously described in melanoma families, has been found in one family. Two
families have R112G mutations, one family has a G67R mutation one has an exon
1a )24 base pair duplication and two families have M53I mutations, bringing the
total of known Scottish families with the M53I mutation to six strongly suggesting
that the M53I mutation originated in Scotland. Work of this type may help clarify
gene environment interaction in the aetiology of melanoma.
Rona M MacKie, Julie Lang et al. CDKN2A mutations in Scottish families with cuta-
neous melanoma: results from 32 newly identified families. Br J Dermatol 2005;
153: 1121–1125.
Effect of sentinel node biopsy on the prognosis of melanoma patients
Sentinel lymph node biopsy (SLNB) in melanoma provides important prognostic
information but it is unclear if SLNB influences the prognosis. 673 melanoma
patients with a primary melanoma were retrospectively studied. In 377 patients the
melanoma was removed without SLNB (preSLNB-group), in 296 patients the mela-
noma was removed with SLNB (SLNB-group). Melanoma related overall survival
was comparable in both groups. However, recurrence free survival was increased in
the SLNB-group due to significantly fewer regional lymph node metastases, whereas
frequencies of loco-regional cutaneous and distant metastases were comparable in
both groups. Thus, there is no prognostic benefit from SLNB in the majority of
melanoma patients.
Gutzmer R, Al Ghazal M, et al. Sentinel node biopsy in melanoma delays recurrence
but does not change melanoma-related survival – a retrospective analysis of 673
patients. Br J Dermatol 2005; 153: 1137–1141.
Induction of toll-like receptors by proprionibacterium acnes
Acne is a chronic disease of the pilosebaceous follicle. Propionibacterium acnes is a key
therapeutic target in acne, yet this bacterium has become resistant to systemic and
topical antibiotics. The authors’ work shows that extracts of P.acnes are able in vitro
both to stimulate keratinocytes proliferation and TLR2, TLR4 and MMP9 expression
by keratinocytes. These facts suggest that P.acnes could play a role in the initial phase
of acne as well as in the induction and the maintenance of the inflammatory phase
of acne. This in vivo and in vitro study opens the way for new therapeutic
approaches to acne with development of molecules against TLR2 and TLR4 signali-
zation.
B Dreno, V Jarousse, et al. Induction of toll-like receptors by proprionibacterium acnes.
Br J Dermatol 2005; 153: 1105–1113.
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